THE RISK FACTORS OF BLOOD-BRAIN BARRIER DISRUPTION AFTER ENDOVASCULAR TREATMENT IN PATIENTS WITH CEREBRAL INFARCTION AND ITS RELATIONSHIP WITH EARLY PROGNOSIS

被引:0
作者
Wang, Yan [1 ]
Cai, Chunqian [2 ]
Hu, Jinquan [3 ,4 ]
机构
[1] Characterist Med Ctr Chinese Peoples Armed Police, Neurotrauma Rehabil, Tianjin 300162, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Acupuncture & Moxibust Dept, Tianjin 300381, Peoples R China
[3] Hubei Univ Med, Taihe Hosp, Dept Neurol, Shiyan 442000, Peoples R China
[4] Hubei Univ Med, The Hosp, 32 Renmin Rd, Shiyan City, Hubei, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2023年 / 39卷 / 01期
关键词
Cerebral infarction; endovascular treatment; blood-brain barrier disruption; prognosis; PERIVASCULAR SPACES;
D O I
10.19193/0393-6384_2023_1_43
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To explore the risk factors of blood-brain barrier disruption after endovascular treatment in patients with cerebral infarction and its relationship with early prognosis, so as to provide more reference for subsequent prognosis evaluation and the development of more targeted therapeutic schedule.Materials and methods: 334 patients with cerebral infarction undergoing endovascular treatment in our hospital from January 2018 to June 2022 were included in this study. They were divided into destruction group (202 cases) and intact group (132 cases) according to the presence or absence of blood-brain barrier disruption. Univariate and multivariate analyses were employed to evaluate the risk factors of blood-brain barrier disruption after endovascular treatment, and analyze the correlation between blood -brain barrier disruption and poor early prognosis.Results: There were statistically significant differences between two groups in concurrent diabetes, randomized blood glucose level, baseline NIHSS score, concurrent cardiogenic embolism, concurrent internal carotid/middle cerebral artery occlusion, poor rate of early prognosis and 90-day follow-up mortality (P<0.05). The results of univariate and multivariate analyses of logistic regression model indicated that baseline NIHSS score, concurrent cardiogenic embolism and middle cerebral artery occlusion were independent influence factors of blood-brain barrier disruption after endovascular treatment (P<0.05). The incidence of blood-brain barrier disruption in poor prognosis subgroup was significantly higher than that in good prognosis subgroup (P<0.05). Multivariate analysis of logistic regression model showed that the occurrence of blood-brain barrier disruption was independently related to poor early prognosis after endovascular treatment (P<0.05).Conclusion: The occurrence of blood-brain barrier disruption after endovascular treatment in patients with cerebral infarction is independently related to baseline NIHSS score, concurrent cardiogenic embolism and middle cerebral artery occlusion. At the same time, patients with blood-brain barrier disruption are at a higher risk of poor early prognosis, so more active treatment should be given clinically to maximize the improvement of clinical outcome.
引用
收藏
页码:279 / 283
页数:5
相关论文
共 50 条
  • [31] The Association Between Neurological Prognosis and the Degree of Blood-Brain Barrier Disruption in Cardiac Arrest Survivors Who Underwent Target Temperature Management
    Jeon, Ga Ram
    Ahn, Hong Joon
    Park, Jung Soo
    Yoo, Insool
    You, Yeonho
    Cho, Yong Chul
    Jeong, Wonjoon
    Kang, Changshin
    Lee, Byung Kook
    NEUROCRITICAL CARE, 2021, 35 (03) : 815 - 824
  • [32] Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system
    Jahnke, Kristoph
    Kraemer, Dale F.
    Knight, Kristin R.
    Fortin, David
    Bell, Susan
    Doolittle, Nancy D.
    Muldoon, Leslie L.
    Neuwelt, Edward A.
    CANCER, 2008, 112 (03) : 581 - 588
  • [33] Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy
    Huang, Jiaming
    Liao, Foqiang
    Tang, Jianhua
    Shu, Xu
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 231
  • [34] Postoperative cerebral infarction after revascularization in patients with moyamoya disease: Incidence and risk factors
    Wang, Jiaxiong
    Jiang, Hanqiang
    Tang, Jinwei
    Lin, Chi
    Ni, Wei
    Gu, Yuxiang
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [35] Selective Toll-Like Receptor 4 Antagonists Prevent Acute Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in Mice
    Takeshi Okada
    Fumihiro Kawakita
    Hirofumi Nishikawa
    Fumi Nakano
    Lei Liu
    Hidenori Suzuki
    Molecular Neurobiology, 2019, 56 : 976 - 985
  • [36] Prognostic factors for acute posterior circulation cerebral infarction patients after endovascular mechanical thrombectomy A retrospective study
    Gao, Jun
    Wen, Changming
    Sun, Jun
    Chen, Di
    Zhang, Donghuan
    Wang, Ning
    Liu, Yifeng
    Wang, Jie
    Zhang, Baochao
    MEDICINE, 2022, 101 (17) : E29167
  • [37] Selective Toll-Like Receptor 4 Antagonists Prevent Acute Blood-Brain Barrier Disruption After Subarachnoid Hemorrhage in Mice
    Okada, Takeshi
    Kawakita, Fumihiro
    Nishikawa, Hirofumi
    Nakano, Fumi
    Liu, Lei
    Suzuki, Hidenori
    MOLECULAR NEUROBIOLOGY, 2019, 56 (02) : 976 - 985
  • [38] Risk factors of prognosis in older patients with severe brain injury after surgical intervention
    Shen, Hanchao
    Liu, Haibing
    He, Jiongzhou
    Wei, Lianqfeng
    Wang, Shousen
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [39] Risk factors of prognosis in older patients with severe brain injury after surgical intervention
    Hanchao Shen
    Haibing Liu
    Jiongzhou He
    Lianqfeng Wei
    Shousen Wang
    European Journal of Medical Research, 28
  • [40] Outcomes and risk factors for infection after endovascular treatment in patients with acute ischemic stroke
    Jiang, Xin
    Hu, Yaowen
    Wang, Jian
    Ma, Mengmeng
    Bao, Jiajia
    Fang, Jinghuan
    He, Li
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (05)